{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:48:52Z","timestamp":1791895732776,"version":"4.3.4"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamadermatol.2020.0465","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:31:35Z","timestamp":1587555095000},"page":"621","source":"Crossref","is-referenced-by-count":147,"title":["Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne"],"prefix":"10.1001","volume":"156","author":[{"given":"Adelaide","family":"Hebert","sequence":"first","affiliation":[{"name":"McGovern Medical School, The University of Texas Health Science Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Thiboutot","sequence":"additional","affiliation":[{"name":"College of Medicine, The Pennsylvania State University, Hershey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Cassiopea Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Gerloni","sequence":"additional","affiliation":[{"name":"Cassiopea SpA, Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fragasso","sequence":"additional","affiliation":[{"name":"Cassiopea SpA, Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mazzetti","sequence":"additional","affiliation":[{"name":"Cassiopea SpA, Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi200011r1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjd.2015.172.issue-S1","article-title":"A global perspective on the epidemiology of acne.","volume":"172","author":"Tan","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9859","key":"doi200011r2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"doi200011r3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/AHMT","article-title":"The epidemiology of acne vulgaris in late adolescence.","volume":"7","author":"Lynn","year":"2016","journal-title":"Adolesc Health Med Ther"},{"key":"doi200011r4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/CCID","article-title":"Adult-onset acne: prevalence, impact, and management challenges.","volume":"11","author":"Rocha","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"doi200011r5","first-page":"S3","article-title":"The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.","volume":"7","author":"Leyden","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"doi200011r6","doi-asserted-by":"publisher","first-page":"15029","DOI":"10.1038\/nrdp.2015.29","article-title":"Acne vulgaris.","volume":"1","author":"Moradi Tuchayi","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"doi200011r7","first-page":"740","article-title":"Acne vulgaris: treatment guidelines from the AAD.","volume":"95","author":"Hauk","year":"2017","journal-title":"Am Fam Physician"},{"issue":"2","key":"doi200011r8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne.","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi200011r9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi200011r10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamadermatol.2017.1297","article-title":"Antibiotic resistance in acne treatment.","volume":"153","author":"Adler","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi200011r11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne.","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol"},{"key":"doi200011r12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/CCID","article-title":"Hormonal treatment of acne vulgaris: an update.","volume":"9","author":"Elsaie","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"doi200011r13","first-page":"1005","article-title":"Androgens have forgotten and emerging roles outside of their reproductive functions, with implications for diseases and disorders.","volume":"1","author":"Dart","year":"2014","journal-title":"J Endocr Disord"},{"issue":"7","key":"doi200011r14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00403-012-1265-x","article-title":"The role of androgen and androgen receptor in skin-related disorders.","volume":"304","author":"Lai","year":"2012","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"doi200011r17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.contraception.2005.07.010","article-title":"Treating acne with oral contraceptives: use of lower doses.","volume":"73","author":"Huber","year":"2006","journal-title":"Contraception"},{"issue":"2","key":"doi200011r19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review.","volume":"18","author":"Layton","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"doi200011r20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1039\/C4MD00049H","article-title":"A full conformational characterization of antiandrogen cortexolone-17a-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopy.","volume":"5","author":"Ferraboschi","year":"2014","journal-title":"MedChemComm"},{"issue":"5","key":"doi200011r21","first-page":"412","article-title":"Cortexolone 17a-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro.","volume":"18","author":"Rosette","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"doi200011r22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery.","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"doi200011r23","first-page":"881","article-title":"Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist.","volume":"54","author":"Celasco","year":"2004","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"doi200011r24","first-page":"197","article-title":"Cortexolone 17a-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro.","volume":"18","author":"Rosette","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"doi200011r25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjd.2011.165.issue-1","article-title":"Cortexolone 17a-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris: a pilot randomized, double-blind comparative study vs. placebo and tretinoin 0\u00b705% cream.","volume":"165","author":"Trifu","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi200011r26","first-page":"563","article-title":"Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with facial acne vulgaris: an open-label phase 2a study.","volume":"18","author":"Mazzetti","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"doi200011r27","first-page":"570","article-title":"A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne.","volume":"18","author":"Mazzetti","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"doi200011r15","year":"2017"},{"key":"doi200011r16","year":"2017"},{"key":"doi200011r18","year":"2018"},{"key":"doi200011r28","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: acne vulgaris: developing drugs for treatment. September 19, 2005. Accessed March 23, 2020. https:\/\/www.federalregister.gov\/documents\/2005\/09\/19\/05-18512\/draft-guidance-for-industry-on-acne-vulgaris-developing-drugs-for-treatment-availability."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2765025\/jamadermatology_hebert_2020_oi_200011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T13:43:41Z","timestamp":1591796621000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2765025"}},"subtitle":["Two Phase 3 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.0465","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737803133.793575042","asserted-by":"object"}]},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}